#United States #New York #Class Action #Cassava Sciences #SAVA

Important Deadline Approaches for Cassava Sciences Shareholders

The Gross Law Firm has issued a crucial notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA), highlighting the February 10, 2025, deadline for joining a class action lawsuit. This legal action pertains to significant issues surrounding the company's leading Alzheimer's disease drug candidate, simufilam.

Context of the Class Action

Cassava Sciences has faced considerable scrutiny following the release of the results from its ongoing Phase 3 study, referred to as the "ReThink-ALZ" study. The study's topline results revealed that simufilam did not meet its primary, secondary, or exploratory endpoints, effectively showing it could not outperform a placebo.

On November 25, 2024, the stock plummeted drastically from $26.48 per share to only $4.30 per share—a staggering decline of approximately 83.76% in just a single day. This drop has raised serious concerns about the company's earlier claims regarding the effectiveness of simufilam in treating Alzheimer's, leading to allegations of misleading statements and the omission of crucial information from investors.

Who Should Participate?

Shareholders who bought SAVA shares during the time period from February 7, 2024, to November 24, 2024, are encouraged to engage with the Gross Law Firm regarding the potential to be appointed as lead plaintiffs in this legal action. Notably, participating as a lead plaintiff is not a requirement to benefit from any potential recovery in this case.

Next Steps for Investors

Interested shareholders should not hesitate to register their information through the designated link. Those who do register will receive access to an integrated portfolio monitoring system that will keep them updated on the case's developments. The looming deadline for this registration is just around the corner—February 10, 2025.

It is vital for investors to act promptly as the repercussions of Cassava's announcements have already shown a significant impact on share prices, and being part of this class action may provide an avenue for recovery for those who suffered financial losses.

Why Choose The Gross Law Firm?

The Gross Law Firm is a nationally acclaimed class-action law firm dedicated to defending the rights of investors. The firm's mission is to ensure that companies adhere strictly to fair business practices, actively engaging in corporate accountability. With a commitment to rectifying situations caused by deceitful business conduct, the firm’s experienced attorneys tirelessly work to recover losses for investors affected by misleading or false information.

For investors who believe they might have been misled by Cassava Sciences, the Gross Law Firm stands ready to assist in navigating the complexities of the legal process.

For more information regarding the class action or to register for participation, Cassava shareholders can contact the Gross Law Firm directly at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

As of today, taking proactive steps could prove crucial for those looking to seek justice and recompense for their losses in the wake of Cassava Sciences' disappointing study results.